Category: Biotech
-
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
As the world increasingly faces the complexities of autoimmune and neurodegenerative diseases, new medical advancements are crucial to better serve patients’ needs. Enter Bionxt Solutions Inc. (BNXT.C), a bioscience innovator making moves with its groundbreaking sublingual (under-the-tongue) drug delivery technology. This technology, now in the process of securing national-level patents globally, represents a shift from…
-
Pubcos extending warrants as summer drags on, hoping for cash injection in months ahead
Canadian-listed, German-based bioscience accelerator BioNxt (BNXT.C) has announced it plans to give warrant holders an additional year to exercise 2022-purchased $0.50 warrants of the company, as its stock steadily climbs up from a low of $0.20 to $0.305 over the past week. BioNxt is going through an FDA trial process on a new oral film…
-
BioNxt Solutions (BNXT.C) to spark marketing as ODF human studies begin
Biotech companies are notoriously difficult to find investor love for in Canada, at least historically, so it’s no surprise that BioNxt Solutions (BNXT.C) is headquartered in Germany. That proximity to German investors is likely to come in handy as the company seeks to start cranking out marketing coverage after several months of prepping their Oral…
-
Zentek (ZEN.V) took a years long path to figure out its incredible biotech potential
Today I found myself going down an investment rabbit hole, chasing information about a company that, to be honest, is wallowing, and has for a while. Unmarketed. Unexplained. Unsimple. Unloved. The company is Zentek (ZEN.V). Back in the day, it was an exploration play known as Zen Graphene Solutions that was more focused on developing…
-
Explaining biotech: Bionxt Solutions (BNXT.C) advances MS product through animal study
Bionxt Solutions Inc. (BNXT.C) has finished a study on a new type of medicine strip that dissolves in your mouth. This strip is designed to treat multiple sclerosis (MS), a condition that affects the brain and nerves. The study looked at how well and how quickly the body absorbs the medicine from this strip compared…
-
Lophos Pharma (MESC.C) now readies for natural and synthetic peyote production
Lophos Pharmaceuticals Corp. (MESC.C), a key player in the Canadian biosciences/psychedelics sector, has made a significant leap forward in the field of psychoactive compound research and development as it has announced the successful finalization of a new synthetic mescaline production protocol, marking a major milestone in the accessibility and study of psychoactive substances. This development…
-
InnoCan Pharma’s (CSE: INNO) investment potential in the Pharmaceuticals Sector: A Balanced View
InnoCan Pharma Corporation, trading on the Canadian Securities Exchange under the symbol INNO, FSE: IP4, and OTC: INNPF, is a pharmaceutical technology company that has garnered attention in the investment community. This article evaluates its potential as an investment option in the pharmaceuticals space, considering both its recent achievements and challenges. Business Model and Strategic…
-
Revive Therapeutics (RVV.C) finds multiple research options moving forward
In Canada, if you look backwards over the timeline, you’ll often find public companies have been other things back in the day. Risen, fallen, tapped out, rolled back, reemerged as a whole new thing. Sometimes this happens several times before a business model catches. Revive Therapeutics (RVV.C) is that rare Canadian smallcap that, while it…
-
Perimeter Medical Imaging AI (PINK.V): After 3 years, it’s half-priced, AI-based, and in FDA trials
If you’ve been around here for a while, like going back three years or so ago, you may recall a former client company in Perimeter Medical Imaging (PINK.V). I really loved repping PINK, because sometimes it’s nice to be able to say that you really ARE trying to cure cancer, and make some profit while…
-
Lucy Loves Luchre: Medexus Pharmaceuticals (MDP.T) is growing fast, keeping the bottom line trim
Hey y’all, Lucy Copperpot back for more analysis of Equity.Guru companies – this one is no longer on the client list, but I asked for permission to dig in anyway because I really think a ton of risk has been removed from Medexus Pharmaceuticals (MDP.T) that the market hasn’t factored in, and that’s a real…